EGFR and non-small cell lung carcinoma: The latter incorporates a panel of prognostic factors associated with BM from NSCLC on the basis of DS‐GPA, including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutation status.